2016 News Releases

Webcast ImageWebcast
Zogenix, Inc. at LEERINK Partners 5th Annual Global Healthcare Conference  (Live)
02/10/16 at 10:40 a.m. ET
Zogenix, Inc. at LEERINK Partners 5th Annual Global Healthcare Conference
Wednesday, February 10, 2016 10:40 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
02/03/16Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
EMERYVILLE, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Bradley S. Galer, M.D., Executive Vice President and CMO, will present a corporate update at the LEERINK Partners 5th Annual Global Healthcare Conference in New York, NY, on February 10, 2016. LEERINK Partners 5th Annual Global... 
Printer Friendly Version
01/19/16Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development program for the Company’s investigational product, ZX008, as a treatment of seizures associated with Dravet syndrome, a rare and catastrophic form of childhood epilepsy. “The FDA grantin... 
Printer Friendly Version
01/11/16Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome
SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the first Phase 3 clinical trial for the Company’s lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome.  “We are extremely pleased to have advanced the ZX008 program to the start of the Phase 3 trial. It is an important step towa... 
Printer Friendly Version